Quantitative changes in cytological molecular markers during primary medical treatment of breast cancer: A pilot study

To quantify the changes in biological molecular markers during primary medical treatment in patients with operable breast cancer and to assess their possible relationship with response to treatment. The treatment group consisted of 31 patients with operable breast carcinomas, median age 57 years (ra...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Breast cancer research and treatment Ročník 53; číslo 1; s. 51 - 59
Hlavní autori:	Makris, A., Powles, T.J., Allred, D.C., Ashley, S.E., Trott, P.A., Ormerod, M.G., Dowsett, M.
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	Dordrecht Springer 01.01.1999 Springer Nature B.V
Predmet:	Adult Aged Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Biomarkers, Tumor - metabolism Biopsy, Needle Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - metabolism Cancer research Cancer therapies Chemotherapy, Adjuvant Female Flow Cytometry Gynecology. Andrology. Obstetrics Humans Immunohistochemistry Ki-67 Antigen - metabolism Mammary gland diseases Medical sciences Methotrexate - administration & dosage Middle Aged Mitoxantrone - administration & dosage Pilot Projects Ploidies Preoperative Care Prospective Studies Proto-Oncogene Proteins c-bcl-2 - metabolism Receptors, Estrogen - metabolism Receptors, Progesterone - metabolism Tamoxifen - administration & dosage Treatment Outcome Tumor Suppressor Protein p53 - metabolism Tumors Human Ploidy Immunocytochemistry Estrogen Tumoral marker Malignant tumor Neoadjuvant treatment Mammary gland diseases TP53 Gene Cohort study Female Mammary gland Progesterone Onc gene Hormonal receptor
ISSN:	0167-6806, 1573-7217
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Abstract	To quantify the changes in biological molecular markers during primary medical treatment in patients with operable breast cancer and to assess their possible relationship with response to treatment. The treatment group consisted of 31 patients with operable breast carcinomas, median age 57 years (range 41-67), treated with four 3-weekly cycles of chemotherapy with Mitoxantrone, methotrexate (+/- mitomycin C), and tamoxifen before surgery. Fine needle aspiration (FNA) was used to obtain samples from patients prior to and at 10 or 21 days post-treatment. The following molecular markers were assessed: estrogen receptor (ER), progesterone receptor (PgR), p53, Bcl-2, and Ki67 measured by immunocytochemistry, and ploidy and S-phase fraction (SPF) by flow cytometry. To evaluate the reproducibility of the technique, repeat FNA was performed in a separate non-treatment control group of 20 patients and the same molecular markers assessed, two weeks after the first sample with no intervening treatment. The non-treatment control group showed a high reproducibility for the measurement of molecular markers from repeat FNA. In the treatment group there was a non-significant reduction in SPF and a significant reduction (p = 0.005) in Ki67. Patients who responded to neoadjuvant therapy were more likely to have a reduction in these two markers than those who failed to respond. Similarly, a reduction in ER scores was observed between the first and second samples (p = 0.04). For PgR, the change between the first and second samples was not significant although there was a significant difference between responders and non-responders (p = 0.03). All nine patients with an increase in PgR were responders. No significant changes in p53 or Bcl-2 were observed during treatment. Molecular markers can be adequately measured from FNA samples prior to and during neoadjuvant therapy. Changes in cellular proliferation and hormone receptors have been shown that may be related to tumour response. These relationships should be assessed in a larger cohort of patients.
AbstractList	To quantify the changes in biological molecular markers during primary medical treatment in patients with operable breast cancer and to assess their possible relationship with response to treatment. The treatment group consisted of 31 patients with operable breast carcinomas, median age 57 years (range 41-67), treated with four 3-weekly cycles of chemotherapy with Mitoxantrone, methotrexate (+/- mitomycin C), and tamoxifen before surgery. Fine needle aspiration (FNA) was used to obtain samples from patients prior to and at 10 or 21 days post-treatment. The following molecular markers were assessed: estrogen receptor (ER), progesterone receptor (PgR), p53, Bcl-2, and Ki67 measured by immunocytochemistry, and ploidy and S-phase fraction (SPF) by flow cytometry. To evaluate the reproducibility of the technique, repeat FNA was performed in a separate non-treatment control group of 20 patients and the same molecular markers assessed, two weeks after the first sample with no intervening treatment. The non-treatment control group showed a high reproducibility for the measurement of molecular markers from repeat FNA. In the treatment group there was a non-significant reduction in SPF and a significant reduction (p = 0.005) in Ki67. Patients who responded to neoadjuvant therapy were more likely to have a reduction in these two markers than those who failed to respond. Similarly, a reduction in ER scores was observed between the first and second samples (p = 0.04). For PgR, the change between the first and second samples was not significant although there was a significant difference between responders and non-responders (p = 0.03). All nine patients with an increase in PgR were responders. No significant changes in p53 or Bcl-2 were observed during treatment. Molecular markers can be adequately measured from FNA samples prior to and during neoadjuvant therapy. Changes in cellular proliferation and hormone receptors have been shown that may be related to tumour response. These relationships should be assessed in a larger cohort of patients. To quantify the changes in biological molecular markers during primary medical treatment in patients with operable breast cancer and to assess their possible relationship with response to treatment. The treatment group consisted of 31 patients with operable breast carcinomas, median age 57 years (range 41-67), treated with four 3-weekly cycles of chemotherapy with Mitoxantrone, methotrexate (+/- mitomycin C), and tamoxifen before surgery. Fine needle aspiration (FNA) was used to obtain samples from patients prior to and at 10 or 21 days post-treatment. The following molecular markers were assessed: estrogen receptor (ER), progesterone receptor (PgR), p53, Bcl-2, and Ki67 measured by immunocytochemistry, and ploidy and S-phase fraction (SPF) by flow cytometry. To evaluate the reproducibility of the technique, repeat FNA was performed in a separate non-treatment control group of 20 patients and the same molecular markers assessed, two weeks after the first sample with no intervening treatment. The non-treatment control group showed a high reproducibility for the measurement of molecular markers from repeat FNA. In the treatment group there was a non-significant reduction in SPF and a significant reduction (p = 0.005) in Ki67. Patients who responded to neoadjuvant therapy were more likely to have a reduction in these two markers than those who failed to respond. Similarly, a reduction in ER scores was observed between the first and second samples (p = 0.04). For PgR, the change between the first and second samples was not significant although there was a significant difference between responders and non-responders (p = 0.03). All nine patients with an increase in PgR were responders. No significant changes in p53 or Bcl-2 were observed during treatment. Molecular markers can be adequately measured from FNA samples prior to and during neoadjuvant therapy. Changes in cellular proliferation and hormone receptors have been shown that may be related to tumour response. These relationships should be assessed in a larger cohort of patients. To quantify the changes in biological molecular markers during primary medical treatment in patients with operable breast cancer and to assess their possible relationship with response to treatment.AIMTo quantify the changes in biological molecular markers during primary medical treatment in patients with operable breast cancer and to assess their possible relationship with response to treatment.The treatment group consisted of 31 patients with operable breast carcinomas, median age 57 years (range 41-67), treated with four 3-weekly cycles of chemotherapy with Mitoxantrone, methotrexate (+/- mitomycin C), and tamoxifen before surgery. Fine needle aspiration (FNA) was used to obtain samples from patients prior to and at 10 or 21 days post-treatment. The following molecular markers were assessed: estrogen receptor (ER), progesterone receptor (PgR), p53, Bcl-2, and Ki67 measured by immunocytochemistry, and ploidy and S-phase fraction (SPF) by flow cytometry. To evaluate the reproducibility of the technique, repeat FNA was performed in a separate non-treatment control group of 20 patients and the same molecular markers assessed, two weeks after the first sample with no intervening treatment.METHODSThe treatment group consisted of 31 patients with operable breast carcinomas, median age 57 years (range 41-67), treated with four 3-weekly cycles of chemotherapy with Mitoxantrone, methotrexate (+/- mitomycin C), and tamoxifen before surgery. Fine needle aspiration (FNA) was used to obtain samples from patients prior to and at 10 or 21 days post-treatment. The following molecular markers were assessed: estrogen receptor (ER), progesterone receptor (PgR), p53, Bcl-2, and Ki67 measured by immunocytochemistry, and ploidy and S-phase fraction (SPF) by flow cytometry. To evaluate the reproducibility of the technique, repeat FNA was performed in a separate non-treatment control group of 20 patients and the same molecular markers assessed, two weeks after the first sample with no intervening treatment.The non-treatment control group showed a high reproducibility for the measurement of molecular markers from repeat FNA. In the treatment group there was a non-significant reduction in SPF and a significant reduction (p = 0.005) in Ki67. Patients who responded to neoadjuvant therapy were more likely to have a reduction in these two markers than those who failed to respond. Similarly, a reduction in ER scores was observed between the first and second samples (p = 0.04). For PgR, the change between the first and second samples was not significant although there was a significant difference between responders and non-responders (p = 0.03). All nine patients with an increase in PgR were responders. No significant changes in p53 or Bcl-2 were observed during treatment.RESULTSThe non-treatment control group showed a high reproducibility for the measurement of molecular markers from repeat FNA. In the treatment group there was a non-significant reduction in SPF and a significant reduction (p = 0.005) in Ki67. Patients who responded to neoadjuvant therapy were more likely to have a reduction in these two markers than those who failed to respond. Similarly, a reduction in ER scores was observed between the first and second samples (p = 0.04). For PgR, the change between the first and second samples was not significant although there was a significant difference between responders and non-responders (p = 0.03). All nine patients with an increase in PgR were responders. No significant changes in p53 or Bcl-2 were observed during treatment.Molecular markers can be adequately measured from FNA samples prior to and during neoadjuvant therapy. Changes in cellular proliferation and hormone receptors have been shown that may be related to tumour response. These relationships should be assessed in a larger cohort of patients.CONCLUSIONMolecular markers can be adequately measured from FNA samples prior to and during neoadjuvant therapy. Changes in cellular proliferation and hormone receptors have been shown that may be related to tumour response. These relationships should be assessed in a larger cohort of patients.
Author	Allred, D.C. Ashley, S.E. Trott, P.A. Ormerod, M.G. Powles, T.J. Makris, A. Dowsett, M.
Author_xml	– sequence: 1 givenname: A. surname: Makris fullname: Makris, A. – sequence: 2 givenname: T.J. surname: Powles fullname: Powles, T.J. – sequence: 3 givenname: D.C. surname: Allred fullname: Allred, D.C. – sequence: 4 givenname: S.E. surname: Ashley fullname: Ashley, S.E. – sequence: 5 givenname: P.A. surname: Trott fullname: Trott, P.A. – sequence: 6 givenname: M.G. surname: Ormerod fullname: Ormerod, M.G. – sequence: 7 givenname: M. surname: Dowsett fullname: Dowsett, M.
BackLink	http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1739492$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/10206072$$D View this record in MEDLINE/PubMed
BookMark	eNp10c9rFDEUB_AgFbutnr1JkOJtbH5MkklvS1FbKIig5yGTfVlTM8maZAr735u2K2rBU0j4fB95752go5giIPSakveUMH6-vqCESKq0oJSq4RlaUaF4pxhVR2hFqFSdHIg8Riel3BJCtCL6BTpuWSKJYit092Uxsfpqqr8DbL-buIWCfcR2X1NIW29NwHMKYJdgMp5N_gG54M2SfdziXfbtZY9n2DzAmsHUGWLFyeGpXUrF1kQL-QKv8c6HVHGpy2b_Ej13JhR4dThP0bePH75eXnU3nz9dX65vOst7XTvRSxgsg146zgehJNdM91aQDRmMUI5LNmlG9OCoE9Y1pbibBuj5pAWfHD9F7x7r7nL6uUCp4-yLhRBMhLSUUWqpudB9g2-fwNu05Nj-NjLKeiWEGhp6c0DL1FoeD-2Pv8fZwNkBmNLm4XLr3Zc_TnHd63t2_shsTqVkcH9Vui_Gx_X4z15bQjxJ2IedpViz8eG_uV_BqqUo
CODEN	BCTRD6
CitedBy_id	crossref_primary_10_1007_s12156_008_0079_8 crossref_primary_10_1007_s12013_014_0327_4 crossref_primary_10_1016_j_clbc_2025_04_019 crossref_primary_10_1016_j_ejca_2016_03_006 crossref_primary_10_3109_07357907_2011_621913 crossref_primary_10_1002_1097_0320_20001101_41_3_166__AID_CYTO2_3_0_CO_2_Y crossref_primary_10_1093_jnci_95_11_766 crossref_primary_10_1097_00001622_199911000_00005 crossref_primary_10_1007_s00428_005_1244_0 crossref_primary_10_1186_1471_2407_9_375 crossref_primary_10_1007_s00280_019_03981_5 crossref_primary_10_1111_his_12649 crossref_primary_10_1038_sj_bjc_6601258 crossref_primary_10_1016_j_prp_2013_08_012 crossref_primary_10_1038_sj_bjc_6600749 crossref_primary_10_1016_j_ejca_2006_01_054 crossref_primary_10_1002_dc_21313 crossref_primary_10_1016_j_anndiagpath_2017_06_004 crossref_primary_10_1126_scitranslmed_3002048 crossref_primary_10_1177_1533033820928435 crossref_primary_10_1002_cncr_25506 crossref_primary_10_1186_bcr1989 crossref_primary_10_1016_j_clon_2012_04_005 crossref_primary_10_1186_bcr1508 crossref_primary_10_1097_PAI_0b013e318234aa12 crossref_primary_10_1186_1477_7819_7_35 crossref_primary_10_1002_dc_22809 crossref_primary_10_1081_CNV_120001147 crossref_primary_10_1158_1078_0432_951s_11_2 crossref_primary_10_1016_j_humpath_2008_06_007 crossref_primary_10_1023_B_BREA_0000003968_45511_3f crossref_primary_10_1093_jjco_hyt130 crossref_primary_10_4132_jptm_2019_11_03 crossref_primary_10_1177_000313480407001215 crossref_primary_10_1007_s10147_015_0897_1 crossref_primary_10_1111_j_1524_4741_2007_00544_x crossref_primary_10_1016_S0002_9610_03_00271_X
Cites_doi	10.1093/jnci/82.19.1539 10.1016/0959-8049(93)90537-P 10.1093/oxfordjournals.bmb.a072911 10.1200/JCO.1995.13.3.547 10.1016/0959-8049(95)00454-8 10.1097/00001622-199511000-00012 10.1016/0092-8674(93)90719-7 10.1002/cyto.990150211 10.1016/S0959-8049(05)80124-8 10.1038/bjc.1994.303 10.1002/1097-0142(19881215)62:12<2507::AID-CNCR2820621210>3.0.CO;2-D 10.1001/archsurg.1990.01410130113018 10.1038/bjc.1991.338 10.1006/bbrc.1993.1377 10.1038/bjc.1994.475 10.1016/0959-8049(93)90534-M 10.1038/bjc.1977.42 10.1038/bjc.1989.256 10.1023/A:1005717924761 10.1038/bjc.1993.111 10.3109/02841869209088893 10.1002/jso.2930290111 10.1007/BF00666008
ContentType	Journal Article
Copyright	1999 INIST-CNRS Copyright Kluwer Academic Publishers Jan 1999
Copyright_xml	– notice: 1999 INIST-CNRS – notice: Copyright Kluwer Academic Publishers Jan 1999
DBID	AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 3V. 7TO 7X7 7XB 88E 8AO 8C1 8FI 8FJ 8FK 8G5 ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH GNUQQ GUQSH H94 K9- K9. M0R M0S M1P M2O MBDVC PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI Q9U 7X8
DOI	10.1023/A:1006179511178
DatabaseName	CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Oncogenes and Growth Factors Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Research Library (Alumni) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials - QC ProQuest Central ProQuest One ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest Research Library AIDS and Cancer Research Abstracts Consumer Health Database (Alumni Edition) ProQuest Health & Medical Complete (Alumni) Consumer Health Database Health & Medical Collection (Alumni) Medical Database Research Library Research Library (Corporate) ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central Basic MEDLINE - Academic
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Research Library Prep ProQuest Central Student Oncogenes and Growth Factors Abstracts ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing Research Library (Alumni Edition) ProQuest Pharma Collection ProQuest Family Health (Alumni Edition) ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Research Library ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Public Health ProQuest Central Basic ProQuest Family Health ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic
DatabaseTitleList	MEDLINE Research Library Prep MEDLINE - Academic
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine
EISSN	1573-7217
EndPage	59
ExternalDocumentID	416807941 10206072 1739492 10_1023_A_1006179511178
Genre	Research Support, U.S. Gov't, P.H.S Clinical Trial Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article
GrantInformation_xml	– fundername: NCI NIH HHS grantid: CA30195 – fundername: NCI NIH HHS grantid: P50 CA58183 – fundername: NCI NIH HHS grantid: P30 CA54174
GroupedDBID	--- -XW -Y2 -~C .86 .GJ .VR 06C 06D 0R~ 0VY 199 1N0 1SB 2.D 203 23N 28- 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2P1 2VQ 2~H 30V 3O- 4.4 406 408 409 40D 40E 53G 5GY 5QI 5VS 67Z 6NX 78A 7X7 88E 8AO 8C1 8FI 8FJ 8G5 8TC 8UJ 95- 95. 95~ 96X AAAVM AABHQ AACDK AAHNG AAIAL AAJBT AAJKR AANXM AANZL AAPKM AARHV AARTL AASML AATNV AATVU AAUYE AAWCG AAYIU AAYQN AAYTO AAYXX ABAKF ABBBX ABBRH ABBXA ABDBE ABDZT ABECU ABFSG ABFTV ABHLI ABHQN ABIPD ABJNI ABJOX ABKCH ABKTR ABLJU ABMNI ABMQK ABNWP ABPLI ABQBU ABQSL ABRTQ ABSXP ABTEG ABTKH ABTMW ABULA ABUWG ABWNU ABXPI ACAOD ACBXY ACDTI ACGFS ACHSB ACHVE ACHXU ACIHN ACKNC ACMDZ ACMLO ACOKC ACOMO ACPIV ACPRK ACSTC ACUDM ACZOJ ADBBV ADHHG ADHIR ADHKG ADIMF ADJJI ADKNI ADKPE ADRFC ADTPH ADURQ ADYFF ADZKW AEAQA AEBTG AEFIE AEFQL AEGAL AEGNC AEJHL AEJRE AEKMD AEMSY AENEX AEOHA AEPYU AETLH AEVLU AEXYK AEZWR AFBBN AFDYV AFDZB AFEXP AFFHD AFFNX AFHIU AFJLC AFKRA AFLOW AFOHR AFQWF AFWTZ AFZKB AGAYW AGDGC AGGDS AGJBK AGMZJ AGQEE AGQMX AGQPQ AGRTI AGVAE AGWIL AGWZB AGYKE AHAVH AHBYD AHIZS AHKAY AHMBA AHPBZ AHSBF AHWEU AHYZX AIAKS AIGIU AIIXL AILAN AITGF AIXLP AJBLW AJRNO AJZVZ AKMHD ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMXSW AMYLF AMYQR AOCGG ARMRJ ASPBG ATHPR AVWKF AXYYD AYFIA AZFZN AZQEC B-. BA0 BBWZM BDATZ BENPR BGNMA BKNYI BPHCQ BSONS BVXVI CAG CCPQU CITATION COF CS3 CSCUP DDRTE DL5 DNIVK DPUIP DU5 DWQXO EBD EBLON EBS EIOEI EJD EMB EMOBN EN4 ESBYG F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNUQQ GNWQR GQ7 GQ8 GRRUI GUQSH GXS H13 HF~ HG5 HG6 HMCUK HMJXF HQYDN HRMNR HVGLF HZ~ I09 IAO ICW IHE IHR IHW IJ- IKXTQ IMOTQ INH INR ITC ITM IWAJR IXC IZIGR IZQ I~X I~Z J-C J0Z JBSCW JCJTX JZLTJ K9- KDC KOV KOW KPH LAK LLZTM M0R M1P M2O M4Y MA- N2Q N9A NB0 NDZJH NPVJJ NQJWS NU0 O9- O93 O9G O9I O9J OAM OVD P19 P2P P9S PF0 PHGZM PHGZT PJZUB PPXIY PQQKQ PROAC PSQYO PT4 PT5 Q2X QOK QOR QOS R4E R89 R9I RHV RNI ROL RPX RRX RSV RZC RZE RZK S16 S1Z S26 S27 S28 S37 S3B SAP SCLPG SDE SDH SDM SHX SISQX SJYHP SMD SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZ9 SZN T13 T16 TEORI TSG TSK TSV TT1 TUC U2A U9L UDS UG4 UKHRP UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WJK WK8 YLTOR Z45 ZGI ZMTXR ZOVNA ZXP ~EX ~KM AAYZH AESKC ALIPV IQODW -53 -5E -5G -BR -EM 3V. ADINQ CGR CUY CVF ECM EIF GQ6 NPM Z7U Z7W Z81 Z82 Z83 Z87 Z8O Z8Q Z8U Z8V Z8W Z91 7TO 7XB 8FK H94 K9. MBDVC PKEHL PQEST PQUKI Q9U 7X8 PUEGO
ID	FETCH-LOGICAL-c349t-546e8c2e46f33857639294c50d08a57f362b92098f1f5cf6f373fb8e43b953bf3
IEDL.DBID	7X7
ISICitedReferencesCount	64
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000079328300006&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	0167-6806
IngestDate	Thu Oct 02 06:57:31 EDT 2025 Sat Nov 08 14:28:26 EST 2025 Wed Feb 19 02:32:59 EST 2025 Mon Jul 21 09:14:13 EDT 2025 Tue Nov 18 22:27:40 EST 2025 Sat Nov 29 07:50:33 EST 2025
IsPeerReviewed	true
IsScholarly	true
Issue	1
Keywords	Human Ploidy Immunocytochemistry Estrogen Tumoral marker Malignant tumor Neoadjuvant treatment Mammary gland diseases TP53 Gene Cohort study Female Mammary gland Progesterone Onc gene Hormonal receptor
Language	English
License	https://www.springernature.com/gp/researchers/text-and-data-mining CC BY 4.0
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c349t-546e8c2e46f33857639294c50d08a57f362b92098f1f5cf6f373fb8e43b953bf3
Notes	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 14 content type line 23 ObjectType-Undefined-3
PMID	10206072
PQID	212475578
PQPubID	36266
PageCount	9
ParticipantIDs	proquest_miscellaneous_69693594 proquest_journals_212475578 pubmed_primary_10206072 pascalfrancis_primary_1739492 crossref_primary_10_1023_A_1006179511178 crossref_citationtrail_10_1023_A_1006179511178
PublicationCentury	1900
PublicationDate	1999-01-00 1999 1999-Jan 19990101
PublicationDateYYYYMMDD	1999-01-01
PublicationDate_xml	– month: 01 year: 1999 text: 1999-01-00
PublicationDecade	1990
PublicationPlace	Dordrecht
PublicationPlace_xml	– name: Dordrecht – name: Netherlands
PublicationTitle	Breast cancer research and treatment
PublicationTitleAlternate	Breast Cancer Res Treat
PublicationYear	1999
Publisher	Springer Springer Nature B.V
Publisher_xml	– name: Springer – name: Springer Nature B.V
References	JN Sarkaria (186871_CR27) 1993; 53 JL Hayward (186871_CR16) 1977; 35 GN Hortobagyi (186871_CR3) 1988; 62 PA Ellis (186871_CR35) 1996; 15 Y Remvikos (186871_CR24) 1991; 64 DP Lane (186871_CR37) 1994; 50 KJ Walker (186871_CR17) 1988; 48 A Montes (186871_CR15) 1993; 29A CK Osborne (186871_CR25) 1984; 44 CK Osborne (186871_CR28) 1985; 45 IN Fernando (186871_CR22) 1994; 70 MI Walton (186871_CR39) 1993; 53 TJ Powles (186871_CR1) 1995; 13 A Howell (186871_CR8) 1987; 47 JC Reed (186871_CR14) 1995; 7 A Billgren (186871_CR32) 1994; 32 A Paradiso (186871_CR12) 1990; 50 PA Ellis (186871_CR11) 1996; 37 T Ohmori (186871_CR40) 1993; 192 (186871_CR19) 1994 A Makris (186871_CR21) 1997; 44 G Bonadonna (186871_CR2) 1990; 82 MU Prey (186871_CR23) 1985; 29 RB Clarke (186871_CR29) 1993; 67 CK Osborne (186871_CR26) 1983; 43 W Gorczyca (186871_CR34) 1994; 15 G Gardin (186871_CR33) 1994; 32 C Dive (186871_CR38) 1992; 3 EDC Anderson (186871_CR5) 1989; 60 DC Allred (186871_CR18) 1990; 125 SRD Johnston (186871_CR30) 1995; 30A SA Rasbridge (186871_CR31) 1994; 70 SM O'Reilly (186871_CR9) 1992; 28 SM Scholl (186871_CR4) 1996; 31A SW Lowe (186871_CR13) 1993; 74 Y Remvikos (186871_CR10) 1993; 29A Scottish Cancer Trials Breast GroupICRF Breast Unit GH (186871_CR7) 1993; 341 L Skoog (186871_CR36) 1992; 31 A Makris (186871_CR20) 1997; 3 WL McGuire (186871_CR6) 1980
References_xml	– volume: 82 start-page: 1539 year: 1990 ident: 186871_CR2 publication-title: J Natl Cancer Inst doi: 10.1093/jnci/82.19.1539 – volume: 29A start-page: 1854 year: 1993 ident: 186871_CR15 publication-title: Eur J Cancer doi: 10.1016/0959-8049(93)90537-P – volume: 50 start-page: 582 issue: 3 year: 1994 ident: 186871_CR37 publication-title: British Medical Bulletin doi: 10.1093/oxfordjournals.bmb.a072911 – volume: 13 start-page: 547 year: 1995 ident: 186871_CR1 publication-title: J Clin Oncol doi: 10.1200/JCO.1995.13.3.547 – volume: 30A start-page: 1663 issue: 11 year: 1995 ident: 186871_CR30 publication-title: Eur J Cancer – start-page: 39 volume-title: Breast Cancer: Experimental and Clinical Aspects year: 1980 ident: 186871_CR6 – volume: 43 start-page: 3583 year: 1983 ident: 186871_CR26 publication-title: Cancer Res – volume: 31A start-page: 1969 issue: 12 year: 1996 ident: 186871_CR4 publication-title: Eur J Cancer doi: 10.1016/0959-8049(95)00454-8 – volume: 7 start-page: 541 year: 1995 ident: 186871_CR14 publication-title: Current Opinion in Oncology doi: 10.1097/00001622-199511000-00012 – volume: 74 start-page: 957 year: 1993 ident: 186871_CR13 publication-title: Cell doi: 10.1016/0092-8674(93)90719-7 – volume: 15 start-page: 169 year: 1994 ident: 186871_CR34 publication-title: Cytometry doi: 10.1002/cyto.990150211 – volume: 28 start-page: 681 year: 1992 ident: 186871_CR9 publication-title: Eur J Cancer doi: 10.1016/S0959-8049(05)80124-8 – volume: 70 start-page: 335 year: 1994 ident: 186871_CR31 publication-title: Br J Cancer doi: 10.1038/bjc.1994.303 – volume: 3 start-page: 417 year: 1992 ident: 186871_CR38 publication-title: Semin Cancer Biol – volume: 48 start-page: 6517 year: 1988 ident: 186871_CR17 publication-title: Cancer Res – volume: 62 start-page: 2507 year: 1988 ident: 186871_CR3 publication-title: Cancer doi: 10.1002/1097-0142(19881215)62:12<2507::AID-CNCR2820621210>3.0.CO;2-D – volume: 125 start-page: 107 year: 1990 ident: 186871_CR18 publication-title: Arch Surg doi: 10.1001/archsurg.1990.01410130113018 – volume: 64 start-page: 501 year: 1991 ident: 186871_CR24 publication-title: Br J Cancer doi: 10.1038/bjc.1991.338 – volume: 192 start-page: 30 year: 1993 ident: 186871_CR40 publication-title: Biochem Biophys Res Commun doi: 10.1006/bbrc.1993.1377 – volume: 70 start-page: 1211 year: 1994 ident: 186871_CR22 publication-title: Br J Cancer doi: 10.1038/bjc.1994.475 – volume: 37 start-page: 36 issue: suppl. year: 1996 ident: 186871_CR11 publication-title: Breast Cancer Res Treat – volume-title: Flow cytometry. A practical approach year: 1994 ident: 186871_CR19 – volume: 341 start-page: 1293 year: 1993 ident: 186871_CR7 publication-title: Lancet – volume: 53 start-page: 1853 year: 1993 ident: 186871_CR39 publication-title: Cancer Res – volume: 45 start-page: 584 year: 1985 ident: 186871_CR28 publication-title: Cancer Res – volume: 47 start-page: 300 year: 1987 ident: 186871_CR8 publication-title: Cancer Res – volume: 29A start-page: 1843 issue: 13 year: 1993 ident: 186871_CR10 publication-title: Eur J Cancer doi: 10.1016/0959-8049(93)90534-M – volume: 44 start-page: 1433 year: 1984 ident: 186871_CR25 publication-title: Cancer Res – volume: 35 start-page: 292 year: 1977 ident: 186871_CR16 publication-title: Br J Cancer doi: 10.1038/bjc.1977.42 – volume: 15 start-page: 112 year: 1996 ident: 186871_CR35 publication-title: Proc Annu Meet Am Soc Clin Oncol – volume: 60 start-page: 223 year: 1989 ident: 186871_CR5 publication-title: Br J Cancer doi: 10.1038/bjc.1989.256 – volume: 50 start-page: 2958 year: 1990 ident: 186871_CR12 publication-title: Cancer Research – volume: 3 start-page: 593 year: 1997 ident: 186871_CR20 publication-title: Clinical Cancer Research – volume: 44 start-page: 65 year: 1997 ident: 186871_CR21 publication-title: Breast Cancer Res Treat doi: 10.1023/A:1005717924761 – volume: 53 start-page: 4413 year: 1993 ident: 186871_CR27 publication-title: Cancer Research – volume: 32 start-page: 63 issue: suppl. year: 1994 ident: 186871_CR32 publication-title: Breast Cancer Research and Treatment – volume: 67 start-page: 606 year: 1993 ident: 186871_CR29 publication-title: Br J Cancer doi: 10.1038/bjc.1993.111 – volume: 31 start-page: 139 issue: 2 year: 1992 ident: 186871_CR36 publication-title: Acta Oncologica doi: 10.3109/02841869209088893 – volume: 29 start-page: 35 year: 1985 ident: 186871_CR23 publication-title: J Surg Oncol doi: 10.1002/jso.2930290111 – volume: 32 start-page: 311 year: 1994 ident: 186871_CR33 publication-title: Breast Cancer Res Treat doi: 10.1007/BF00666008
SSID	ssj0009709
Score	1.8149233
Snippet	To quantify the changes in biological molecular markers during primary medical treatment in patients with operable breast cancer and to assess their possible...
SourceID	proquest pubmed pascalfrancis crossref
SourceType	Aggregation Database Index Database Enrichment Source
StartPage	51
SubjectTerms	Adult Aged Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Biomarkers, Tumor - metabolism Biopsy, Needle Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - metabolism Cancer research Cancer therapies Chemotherapy, Adjuvant Female Flow Cytometry Gynecology. Andrology. Obstetrics Humans Immunohistochemistry Ki-67 Antigen - metabolism Mammary gland diseases Medical sciences Methotrexate - administration & dosage Middle Aged Mitoxantrone - administration & dosage Pilot Projects Ploidies Preoperative Care Prospective Studies Proto-Oncogene Proteins c-bcl-2 - metabolism Receptors, Estrogen - metabolism Receptors, Progesterone - metabolism Tamoxifen - administration & dosage Treatment Outcome Tumor Suppressor Protein p53 - metabolism Tumors
Title	Quantitative changes in cytological molecular markers during primary medical treatment of breast cancer: A pilot study
URI	https://www.ncbi.nlm.nih.gov/pubmed/10206072 https://www.proquest.com/docview/212475578 https://www.proquest.com/docview/69693594
Volume	53
WOSCitedRecordID	wos000079328300006&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVPQU databaseName: Consumer Health Database customDbUrl: eissn: 1573-7217 dateEnd: 20171231 omitProxy: false ssIdentifier: ssj0009709 issn: 0167-6806 databaseCode: M0R dateStart: 19970101 isFulltext: true titleUrlDefault: https://search.proquest.com/familyhealth providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1573-7217 dateEnd: 20171231 omitProxy: false ssIdentifier: ssj0009709 issn: 0167-6806 databaseCode: 7X7 dateStart: 19970101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1573-7217 dateEnd: 20171231 omitProxy: false ssIdentifier: ssj0009709 issn: 0167-6806 databaseCode: BENPR dateStart: 19970101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database customDbUrl: eissn: 1573-7217 dateEnd: 20171231 omitProxy: false ssIdentifier: ssj0009709 issn: 0167-6806 databaseCode: 8C1 dateStart: 19970101 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest – providerCode: PRVPQU databaseName: Research Library customDbUrl: eissn: 1573-7217 dateEnd: 20171231 omitProxy: false ssIdentifier: ssj0009709 issn: 0167-6806 databaseCode: M2O dateStart: 19970101 isFulltext: true titleUrlDefault: https://search.proquest.com/pqrl providerName: ProQuest – providerCode: PRVAVX databaseName: SpringerLINK Contemporary 1997-Present customDbUrl: eissn: 1573-7217 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0009709 issn: 0167-6806 databaseCode: RSV dateStart: 19970101 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB5BixAS4k0JpcUHDlwCXj9imwtaqlZcuhQE0t6ixLGllbrJdpOtxL_Hr2xbpHLhYimKE9me8czY8_gA3skaN5YrmxPKSM5MxXJliiYXVmCtuawa0QSwCTGbyflcnaXYnD6FVY4yMQjqptP-jvyjE7FMcMdfn1cXuQeN8s7VhKBxF3Y9arZnczEXVzV3RYzw8KW9C4mLvyr7eOXt7IvJxEOsXVNKD1dV79bHRmCL2y3PoIFOHv_n2J_Ao2R6omnkladwx7TP4P5pcq4_h8vvm6oNOWdOAqKYEdyjRYv072EUkWg5wumipQ_sWfcoJjqiVSxbgZbR84O2Eeyos6j2oe8D0p7F1p_QFK0W592AQm3bF_Dr5Pjn0dc8wTLkmjI15JwVRmpiWGHd-dadV7yJxTTHDZYVF9apxFoRrKSdWK6t6yWoraVhtFac1pa-hJ22a80rQNo4605WxoqGMuONJ2dNaUoVZ8atV5PBh5EupU41yz10xnkZfOeEltPyBiEzeL_9IM379q4HNwh91V9QxRTJYH8kZpn2dV9uKZnB2-1btyG9l6VqTbfpy0IVPtuZZbAXueXaQAgusCCv__nnfXgQS0P4a543sDOsN-YA7unLYdGvDwOHh1a6Vh5NDmH3y_Hs7Id7OsWhJd_-ADI1B6U
linkProvider	ProQuest
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1dT9RAFL1BNGJC_EYLIvOgiS_V7nx0OiTGbFQCAVZNMOGttNOZZBO2XbddDD_K_8jcTruACb7x4HOnk7Zz5s6Zzrn3ALxJ8qiwQtmQMk5DbjIeKhMXobQy0lokWSGL1mxCjkbJ8bH6vgR_-lwYlFX2MbEN1EWl8R_5BxdiuRQOX5-mv0I0jcLD1d5Bw6Ni35z_dju2-uPeFze8bynd-Xr0eTfsTAVCzbhqQsFjk2hqeGzd7syxbSQIXIuoiJJMSOsCeq5opBI7sEJb10oymyeGs1wJllvm-r0DdzluhFApSL9d1viVXlGCpcTjJIr_qiSEZMHxmcEALd2uLIKr06x242G9kcbNTLdd8XYe_Wff6jE87Kg1Gfq58ASWTPkU7h924oFncPZjnpVtTp2L8MRnPNdkXBJ93vRLAJn0dsFkgsKlWU18IieZ-rIcZOJPtshCoU8qS3KU9jdE4xSabZMhmY5Pq4a0tXufw89bees1WC6r0rwEoo1jr0lmrCwYN0gOHVvUjCnBjRufIoD3PQ5S3dVkR2uQ07TVBlCWDtNrwAng3eKG7r1vbrp5DViX7SVTXNEANnrwpF3cqtMFcgLYWlx1AQdPkbLSVPM6jVWM2dw8gBcenVcehEZxJOn6P3vegpXdo8OD9GBvtL8BD3wZDPyl9QqWm9ncbMI9fdaM69nrdnYROLltiF4APKtdXQ
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3LbtQwFL0qBVVIqLwhlFIvQGIT6vEjtitV1YgyoiodFQRSd2ni2NJInWSYZIr6afwddpxMW6Sy64J1nCiJj6-P7XPvAXgrc1xYrmxMKCMxMxmLlUmKWFiBteYyK0TRmk2I8VienKjjFfjd58J4WWUfE9tAXVTa75FvuxDLBHf42radKuJ4f7Q3-xl7Ayl_0Nq7aQSEHJqLX271Vu8e7LuufkfI6NP3j5_jzmAg1pSpJuYsMVITwxLrVmqOeXuywDTHBZYZF9YF91wRrKQdWK6tayWozaVhNFec5pa6596Bu4Jx4sv2H-Fvl_V-RVCX-LLiicTJX1WFPHFw3GYw8PZuVybEB7Osdn1jg6nGzay3nf1GD__j__YI1jvKjYZhjDyGFVM-gbWjTlTwFM6_LrKyzbVzkR-FTOgaTUqkL5p-akDT3kYYTb2gaV6jkOCJZqFcB5qGEy-0VO6jyqLcS_4bpP3Qmu-gIZpNzqoGtTV9n8GPW_nq57BaVqV5CUgbx2plZqwoKDOeNDoWqSlVnBnXV0UEH3pMpLqr1e4tQ87SVjNAaDpMr4EogvfLG7rvvrnp5jWQXbYXVDFFItjogZR28axOlyiKYGt51QUif7qUlaZa1GmiEp_lzSJ4EZB65UUITrAgr_755C1Yc8hMvxyMDzfgfqiO4Xe6XsNqM1-YTbinz5tJPX_TDjQEp7eN0D_FMmYj
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Quantitative+changes+in+cytological+molecular+markers+during+primary+medical+treatment+of+breast+cancer+%3A+A+pilot+study&rft.jtitle=Breast+cancer+research+and+treatment&rft.au=MAKRIS%2C+A&rft.au=POWLES%2C+T.+J&rft.au=ALLRED%2C+D.+C&rft.au=ASHLEY%2C+S.+E&rft.date=1999&rft.pub=Springer&rft.issn=0167-6806&rft.volume=53&rft.issue=1&rft.spage=51&rft.epage=59&rft_id=info:doi/10.1023%2FA%3A1006179511178&rft.externalDBID=n%2Fa&rft.externalDocID=1739492
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0167-6806&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0167-6806&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0167-6806&client=summon